entertainment -WSS

entertainment

author：explore 2025-10-01 17:56:36 - browse：2

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Why Talkspace is targeting Medicare, a tricky market

hotspot

WSS

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Microsoft's Peter Lee: Generative AI could help doctors be more human

For AI in health care standards, federal regulators join with industry group

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Readout Newsletter: BridgeBio, Akero, and human embryo models

Immune cells and nerve overgrowth may explain recurring UTI pain

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

In age of alternative facts, a scholarly course on calling out crap

The public health thinking behind the CDC’s new Covid guidance

Wildfire smoke exposes gaps in outdoor worker protections

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

As demand for Covid shots wanes, Moderna seeks its next success

Military medical care influenced by rank and race, new study finds

Medical records are filled with copy

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

In age of alternative facts, a scholarly course on calling out crap

The untold story of TV’s first prescription drug ad

knowledge

Data integrity in scientific journals requires "effort" by publishers, institutions

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Readers respond to H5N1 and livestock movements, and more

Ancient Greek ideas underpin modern concepts of pregnancy

Lack of health data on LGBTQ+ people has serious consequences

First over

hotspot

focus

hotspot

leisure time